- Safe in Phase I/II clinical trials
- Small amount of BMP6 and autologous ABC carrier
OSTEOGROW has already been tested in patients undergoing high tibial osteotomy (HTO; n=20, PhI/II completed) and in patients with a closed distal radius fracture (DRF; n=32, PhI completed). Preliminary results and final data analysis indicate that OSTEOGROW accelerates the healing of trabecular bone in humans. Available safety data suggests good OSTEOGROW safety.
OSTEOGROW-A is OSTEOGROW supplemented with allograft from a bone bank currently tested in an ongoing multicentre double-blinded randomized Phase II clinical trial in patients undergoing posterolateral lumbar interbody fusion (PLIF; n=143, PhII, follow-up 20 months - April 2023).
OSTEOGROW – C is OSTEOGROW in combination with tricalcium phosphate (TCP) ceramics. A compression resistant matrix (CRM) is added to enhance the rheological and biomechanical properties of the implant for use in patients with bone fracture nonunions for whom there is no biological drug therapy available.